SCHEDULE: Versant Exits LAVA Therapeutics, Sells All Shares

Versant Venture Capital and related entities have fully divested their stake in LAVA Therapeutics N.V., selling over 2.9 million shares for approximately $4.07 million.

Summary

• Versant Venture Capital VI, L.P. and Versant Vantage I, L.P., along with their affiliated entities, have fully divested their beneficial ownership in LAVA Therapeutics N.V.
• On September 19, 2025, Versant VI sold 2,370,533 Common Shares at a weighted average price of $1.4014 per share, generating approximately $3,322,064.95 in proceeds.
• On the same date, Vantage LP sold 532,870 Common Shares at a weighted average price of $1.4014 per share, for aggregate proceeds of approximately $746,764.02.
• Following these transactions, the Reporting Persons no longer beneficially own more than 5% of LAVA Therapeutics N.V.'s outstanding Common Shares.

Sentiment

Score: 3

Explanation: The complete divestment by a major venture capital firm is a significant negative signal, indicating a loss of confidence or a strategic exit. While the company itself did not issue the filing, the action of a major shareholder can heavily influence market perception and stock performance.

Negatives

• A significant institutional investor, Versant Venture Capital, has fully divested its stake in LAVA Therapeutics N.V., potentially signaling a lack of confidence in the company's future prospects.
• The sale of over 2.9 million shares could exert downward pressure on the stock price due to increased supply in the market.
• The exit of a major venture capital firm might reduce institutional interest and investor sentiment towards LAVA Therapeutics.

Risks

• The complete divestment by a major venture capital firm like Versant could be interpreted by the market as a negative signal regarding LAVA Therapeutics' long-term potential or current operational challenges.
• Increased selling pressure from such a large block of shares entering the market could lead to stock price volatility and decline.
• Loss of a significant institutional shareholder may impact future capital raising efforts or strategic partnerships.

Future Outlook

The filing does not contain any forward-looking statements or guidance from LAVA Therapeutics N.V. management, as it is a disclosure from a selling shareholder.

Industry Context

The divestment by a prominent venture capital firm like Versant in a biotechnology company such as LAVA Therapeutics N.V. could reflect a strategic portfolio reallocation or a reassessment of the company's drug development pipeline and market potential. In the biotech sector, VC exits can sometimes precede or follow significant clinical trial results, regulatory milestones, or shifts in competitive landscape, though this filing does not provide specific reasons for the sale.

Stakeholder Impact

• Shareholders: Existing shareholders may experience downward pressure on the stock price and a decrease in investor confidence due to the exit of a major institutional investor.
• Potential Investors: May view the company less favorably, potentially impacting future investment interest.

Key Dates

Recommendation

The complete divestment by a significant venture capital firm like Versant Venture Capital, which was an early investor, typically signals a lack of conviction in the company's future growth prospects or a belief that the stock has reached its peak potential from their perspective. This action removes a large institutional holder, potentially increasing selling pressure and reducing overall market confidence. For a seasoned investor, this would be a strong signal to consider exiting or reducing their position, as the departure of a knowledgeable insider often precedes further stock depreciation or prolonged underperformance.

Keywords

LAVA Therapeutics, Versant Venture Capital, Schedule 13D/A, Share Sale, Beneficial Ownership, Institutional Investor, Biotechnology, Divestment, SEC Filing